Boston Medical Center
Boston, Massachusetts, 02116, United States
Location status: Recruiting
Location contact
Jose Baez, MD
CONTACT
Natalia Morone, MD MS
CONTACT
NCT Number: NCT06106191
This study will identify unique signatures that people have which can cause pain by evaluating biological, psychological, and social markers using artificial intelligence. These markers can be used to accurately predict the response of diverse individuals with chronic low back pain (cLBP) to Mindfulness-Based Stress Reduction. This will help enhance clinician decision-making and the targeted treatment of chronic pain.
The overall objective is to use a unique machine learning (ML) approach to determine the biomarker signature of persons undergoing mindfulness based stress reduction (MBSR) treatment for their chronic low back pain (cLBP). This signature will facilitate clinical prediction and monitoring of patient response to MBSR treatment.
The design of the study is a single-arm clinical trial of the evidence-based MBSR program for patients with cLBP.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02116, United States
Location status: Recruiting
Jose Baez, MD
CONTACT
Natalia Morone, MD MS
CONTACT
UG3 Phase Overview. The first 24-months of the project will be dedicated to performing machine learning modeling to identify candidate predictive and monitoring markers of cLBP response to MBSR, prior to the full clinical trial in the UH3 phase. We will also refine our procedures such as recruitment and outcomes assessment with 50 persons during the UG3 phase.
UH3 Phase Overview. Biopsychosocial markers will be identified of the response of diverse cLBP patients to MBSR (N=300) from comprehensive pain assessment and biopsychosocial data, including pain intensity and pain interference, physical activity, sleep, and heart rate for a 6-month period. Data will be collected and used for training and testing ML models. The MBSR program is evidence-based and meets weekly in a group via Zoom for 8-weeks for 90 minutes per week. Measures to determine biomarkers will be obtained at baseline (T1), four-weeks (T2), program completion (T3), four months (T4), and six months (T5). The main outcome timepoint with be at six months (T5), which allows time for durability of effects to be determined. The PEG (Pain, Enjoyment, General activity), obtained through online self-report surveys is the main outcome measure. Secondary outcomes of physical and psychological function will be self-report and obtained online, or if the patient prefers, by telephone, and physical activity, sleep, and heart rate variability will be collected by Fitbit.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ordinary activities like breathing, eating, and walking are turned into a meditation by creating greater awareness of the moment-to-moment sensations, emotions, thoughts and behaviors that arise during these activities.
Understanding pain from a mind-body perspective and viewing pain as a stressor on physical sensations, thoughts, emotions, and behavior.
Discussion on patients' use of mindfulness to work with pain and pain-themed meditations.
Time frame: 6 months
The PEG is a 3-question scale: "pain average", "interference with general activity" and "interference with enjoyment of life". Each question is on a 0-10 scale, and total PEG is the average. Scores can range from 0-30 and <12=Mild,12 to <21 = Moderate, 21 to 30 = Severe chronic pain.
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The total score is determined by adding together the scores of each of the four items. Scores are rated as normal (0-2), mild (3-5), moderate (6-8), and severe (9-12). Total score ≥3 for first 2 questions suggests anxiety. Total score ≥3 for last 2 questions suggests depression.
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
This is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." GAD-7 total score for the seven items ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms.
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The PSEQ is a 10-question survey that measures the confidence of a person with persistent pain to do a range of activities while in pain. The total score ranges from 0 to 60. High PSEQ scores are strongly associated with clinically- significant functional levels and provide a useful gauge for evaluating outcomes in chronic pain patients. Higher scores (and a higher percentile) represent higher confidence to function with pain.
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The Pain Catastrophizing Scale (PCS) measures three aspects of catastrophic cognitions about pain-rumination, magnification, and helplessness. It consists of 13 items scored from 0 to 4, with a total range of 0 to 52. Higher scores are less favorable and a score of more than 30 points may indicate clinical relevance.
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The PROMIS-29 v2. 0 profile measure assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items for each domain. HIgher scores indicate greater pain intensity.
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
Patient Global Impression of Change (PGIC) will be used to assess this outcome. A score of 1=No change (or condition has got worse), 2 = Almost the same, hardly any change at all, 3 = A little better, but no noticeable change, 4 = Somewhat better, but the change has not made any real difference, 5 = Moderately better, and a slight but noticeable change, 6 = Better, and a definite improvement that has made a real and worthwhile difference 7 = A great deal better, and a considerable improvement that has made all the difference. A 2-point change is significant from the last reported score
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The CAMS-R is a 12-item measure designed to capture a broad conceptualization of mindfulness with language that is not specific to any particular type of meditation training. Items 2, 6, and 7 are reverse-scored. After appropriate reversals, values for items 1 - 12 are summed. Higher values reflect greater mindful qualities.
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
The PROMIS 6a scale is composed of 6 items developed to assess the domain of sleep disturbances in the past 7 days. The first two scale items assess sleep quality and the following 4 items assess domains of restfulness, sleep problems, and difficulty falling asleep. Each question has five response options ranging in value from one to five. To find the total raw score for a short so the range of scores is 6 to 30.
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
One question assesses sleep duration. This survey measures the impact of pain on the quality of sleep
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
Six questions ask about treatment expectancy. It assesses participants' attitudes towards and perceptions of treatment components that associated with nont specific treatment effects
Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months
12 questions that ask about social support in regards to how many people a person sees and talk to regularly. The total score is calculated by finding the sum of the all items with a higher score indicating more social engagement.
Contact information is provided by the study sponsor or research team.
Jose Baez, MD
CONTACT
Natalia Morone, MD MS
CONTACT
Boston Medical Center
Other
Acronym: IMPACT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04824547
Behavior, Chronic Low-back Pain
Ankara, Altindag, Turkey (Türkiye)
View Trial DetailsNCT06355414
Behavior, Behavioral Symptoms
Baltimore, Maryland, United States
View Trial DetailsNCT06891625
Back Disorder, Chronic Low-back Pain
Huddinge, Sweden
View Trial DetailsNCT04980612
Chronic Low-back Pain, Neurologic Manifestations
San Francisco, California, United States
View Trial Details